SG&A Expense (Quarterly) Chart

Historical SG&A Expense (Quarterly) Data

View and export this data back to 2009. Upgrade now.
Date Value
December 31, 2023 -9.867M
September 30, 2023 38.00M
June 30, 2023 42.53M
March 31, 2023 29.82M
December 31, 2022 -22.27M
September 30, 2022 39.39M
June 30, 2022 38.76M
March 31, 2022 40.94M
December 31, 2021 -51.36M
September 30, 2021 61.08M
June 30, 2021 71.05M
March 31, 2021 46.30M
December 31, 2020 -28.80M
September 30, 2020 53.94M
June 30, 2020 47.47M
March 31, 2020 25.33M
December 31, 2019 15.41M
September 30, 2019 14.94M
June 30, 2019 12.00M
March 31, 2019 8.626M
December 31, 2018 11.70M
September 30, 2018 7.462M
June 30, 2018 8.266M
March 31, 2018 5.797M
December 31, 2017 8.414M
Date Value
September 30, 2017 5.265M
June 30, 2017 5.434M
March 31, 2017 4.231M
December 31, 2016 6.002M
September 30, 2016 3.813M
June 30, 2016 4.144M
March 31, 2016 3.562M
December 31, 2015 -0.1356M
September 30, 2015 3.953M
June 30, 2015 4.434M
March 31, 2015 3.369M
December 31, 2014 -0.8249M
September 30, 2014 4.775M
June 30, 2014 4.706M
March 31, 2014 4.542M
December 31, 2013 -2.635M
September 30, 2013 6.392M
June 30, 2013 6.335M
March 31, 2013 4.718M
December 31, 2012 -1.467M
September 30, 2012 3.767M
June 30, 2012 3.943M
March 31, 2012 3.313M
December 31, 2011 -2.487M
September 30, 2011 7.466M

SG&A Expense Definition

SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.

Read full definition.

SG&A Expense (Quarterly) Range, Past 5 Years

-51.36M
Minimum
Dec 2021
71.05M
Maximum
Jun 2021
24.46M
Average
38.00M
Median
Sep 2023

SG&A Expense (Quarterly) Benchmarks

Incyte Corp 300.30M
Novartis AG 2.84B
Immatics NV 11.17M
Affimed NV 6.642M
InflaRx NV 4.562M